| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
|
J Clin Oncol
|
2007
|
5.13
|
|
2
|
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
|
Science
|
2011
|
4.46
|
|
3
|
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.
|
J Clin Oncol
|
2010
|
3.78
|
|
4
|
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
|
J Natl Compr Canc Netw
|
2011
|
2.73
|
|
5
|
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
|
J Allergy Clin Immunol
|
2008
|
2.42
|
|
6
|
New advances in ovarian cancer.
|
Oncology (Williston Park)
|
2010
|
2.27
|
|
7
|
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
|
Proc Natl Acad Sci U S A
|
2012
|
1.81
|
|
8
|
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
|
J Clin Oncol
|
2006
|
1.65
|
|
9
|
Influence of patients' preferences and treatment site on cancer patients' end-of-life care.
|
Cancer
|
2010
|
1.55
|
|
10
|
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
|
Cancer
|
2013
|
1.52
|
|
11
|
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
|
Clin Cancer Res
|
2012
|
1.35
|
|
12
|
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.
|
PLoS One
|
2012
|
1.31
|
|
13
|
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
|
Clin Cancer Res
|
2008
|
1.23
|
|
14
|
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
|
Eur J Cancer
|
2013
|
1.17
|
|
15
|
Epithelial ovarian cancer.
|
J Natl Compr Canc Netw
|
2011
|
1.16
|
|
16
|
Ovarian cancer, version 2.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.13
|
|
17
|
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
|
PLoS One
|
2013
|
1.11
|
|
18
|
Cancer- and chemotherapy-induced anemia.
|
J Natl Compr Canc Netw
|
2012
|
1.10
|
|
19
|
Ovarian cancer, version 3.2012.
|
J Natl Compr Canc Netw
|
2012
|
1.08
|
|
20
|
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
1.06
|
|
21
|
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
|
J Clin Oncol
|
2009
|
1.05
|
|
22
|
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.
|
J Altern Complement Med
|
2009
|
1.05
|
|
23
|
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
|
Gynecol Oncol
|
2009
|
1.03
|
|
24
|
Comparison of the quality of life of early and advanced stage ovarian cancer survivors.
|
Gynecol Oncol
|
2009
|
1.01
|
|
25
|
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
|
Clin J Am Soc Nephrol
|
2010
|
1.00
|
|
26
|
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
|
Gynecol Oncol
|
2005
|
0.99
|
|
27
|
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.
|
Gynecol Oncol
|
2005
|
0.99
|
|
28
|
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
|
Gynecol Oncol
|
2005
|
0.96
|
|
29
|
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
|
Gynecol Oncol
|
2004
|
0.94
|
|
30
|
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
|
Gynecol Oncol
|
2012
|
0.94
|
|
31
|
Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease.
|
J Psychosoc Oncol
|
2010
|
0.92
|
|
32
|
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
|
Gynecol Oncol
|
2004
|
0.91
|
|
33
|
Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients.
|
Integr Cancer Ther
|
2010
|
0.91
|
|
34
|
Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels.
|
Gynecol Oncol
|
2011
|
0.90
|
|
35
|
POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing.
|
Cancer
|
2014
|
0.89
|
|
36
|
Bevacizumab rechallenge after first line maintenance bevacizumab.
|
Gynecol Oncol
|
2012
|
0.88
|
|
37
|
CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.
|
Clin Chem
|
2010
|
0.87
|
|
38
|
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.
|
Gynecol Oncol
|
2013
|
0.84
|
|
39
|
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
|
Gynecol Oncol
|
2005
|
0.83
|
|
40
|
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
|
Oncotarget
|
2014
|
0.82
|
|
41
|
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
|
Gynecol Oncol
|
2004
|
0.80
|
|
42
|
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
|
Gynecol Oncol
|
2009
|
0.80
|
|
43
|
Hopelessness and complementary therapy use in patients with ovarian cancer.
|
Cancer Nurs
|
2013
|
0.78
|
|
44
|
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.
|
Gynecol Oncol
|
2003
|
0.78
|
|
45
|
Anti-angiogenic agents in ovarian cancer: dawn of a new era?
|
Curr Oncol Rep
|
2011
|
0.77
|
|
46
|
Ovarian cancer clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2004
|
0.77
|
|
47
|
Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.
|
J Psychosoc Oncol
|
2012
|
0.77
|
|
48
|
New biologic agents for the treatment of gynecologic cancers.
|
Hematol Oncol Clin North Am
|
2012
|
0.75
|
|
49
|
Chemotherapy hypersensitivity reactions in ovarian cancer.
|
J Natl Compr Canc Netw
|
2014
|
0.75
|